Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Research

• Publication date

  2011-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-10-3259PMID 21402711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer immunology.

  2011cited by this paper
• Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

  2010cited by this paper
• Peptide inhibitors of transforming growth factor‐β enhance the efficacy of antitumor immunotherapy

  2009cited by this paper
• Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor‐specific CD8+ T cells

  2009cited by this paper
• In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

  2009cited by this paper
• Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

  2009cited by this paper
• Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines

  2008cited by this paper
• Cancer Immunology

  2008cited by this paper
• Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8[+] T cells

  2008cited by this paper
• Immunogenic cancer cell death: a key-lock paradigm.

  2008cited by this paper
• Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation.

  2007cited by this paper
• Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection

  2007cited by this paper
• The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo1

  2007cited by this paper
• Multiple-Cytokine-Producing Antiviral CD4 T Cells Are Functionally Superior to Single-Cytokine-Producing Cells

  2007cited by this paper
• Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

  2007cited by this paper
• Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

  2007cited by this paper
• Toll-like receptor ligands energize peptide vaccines through multiple paths.

  2007cited by this paper
• Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-β gene

  2007cited by this paper
• Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo.

  2006influential reference
• HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

  2006cited by this paper
• Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1

  2006cited by this paper
• Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

  2005cited by this paper
• Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma

  2005cited by this paper
• Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

  2004cited by this paper
• IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

  2004cited by this paper
• IL-15/IL-15Rα-mediated avidity maturation of memory CD8 + T cells

  2004cited by this paper
• Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN

  2004cited by this paper
• Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway

  2003cited by this paper
• Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.

  2003cited by this paper
• Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

  2002cited by this paper
• Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

  2001cited by this paper
• Tumours can act as adjuvants for humoral immunity

  2001cited by this paper
• CD40 signaling in human dendritic cells is initiated within membrane rafts

  2000cited by this paper
• Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1

  2000cited by this paper
• Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

  1999cited by this paper
• High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

  1999cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides

  1998cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

  1996cited by this paper
• Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

  1996cited by this paper
• Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

  1989cited by this paper
• Biological behavior of malignant melanoma cells correlated to their survival in vivo.

  1975cited by this paper

• Anti-PD-1 amplifies costimulation in melanoma-infiltrating Th1-like Foxp3+ regulatory T cells to alleviate local immunosuppression

  2025cites this paper
• Endogenous double-stranded RNA: Bridging immune activation and cancer therapeutics

  2025cites this paper
• A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model

  2024cites this paper
• β-Glucan-modified nanoparticles with different particle sizes exhibit different lymphatic targeting efficiencies and adjuvant effects

  2024cites this paper
• The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

  2024influential citation
• Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG‐E8

  2024cites this paper
• CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes.

  2023cites this paper
• EDA-E7 Activated DCs Induces Cytotoxic T Lymphocyte Immune Responses against HPV Expressing Cervical Cancer in Human Setting

  2023cites this paper
• Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

  2022cites this paper
• Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

  2022cites this paper
• Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance

  2022cites this paper
• Roles of Toll-Like Receptor 3 in Human Tumors

  2021cites this paper
• Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

  2021cites this paper
• Small Molecule Inhibition of Glycogen Synthase Kinase-3 in Cancer Immunotherapy.

  2019cites this paper
• Mannose‐Modified Multi‐Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells

  2019cites this paper
• Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer

  2019cites this paper
• Targeting and Specific Activation of Antigen‐Presenting Cells by Endogenous Antigen‐Loaded Nanoparticles Elicits Tumor‐Specific Immunity

  2019cites this paper
• Immunocorrelates of CAF family adjuvants.

  2018cites this paper
• Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.

  2018cites this paper
• Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.

  2018cites this paper
• WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy

  2018cites this paper
• Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.

  2018cites this paper
• The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

  2017cites this paper
• Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity

  2017cites this paper
• Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease

  2017cites this paper
• Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma

  2017cites this paper
• The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

  2017cites this paper
• The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects

  2017cites this paper
• Innate signaling by mycolate esters of the cell wall of Mycobacterium tuberculosis and relevance for the development of adjuvants for subunit vaccines

  2017influential citation
• Localized Multi‐Component Delivery Platform Generates Local and Systemic Anti‐Tumor Immunity

  2017cites this paper
• Development of C5AR-Targeted Nanoparticles for Delivery of Vaccines

  2017cites this paper
• Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination

  2016cites this paper
• Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses

  2016cites this paper
• Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.

  2016cites this paper
• Fibronectin-targeted drug delivery in cancer.

  2016cites this paper
• A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation.

  2016cites this paper
• IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

  2016cites this paper
• Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells

  2016cites this paper
• An Enzyme‐Directed Imidazoquinoline for Cancer Immunotherapy

  2016cites this paper
• Effective Delivery of Antigen-Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection.

  2016cites this paper
• A Versatile Vector for In Vivo Monitoring of Type I Interferon Induction and Signaling

  2016cites this paper
• EXTRACELLULAR MATRIX-DERIVED NANOPARTICLES FOR IMAGING AND IMMUNOMODULATION

  2016cites this paper
• Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors

  2015cites this paper
• IAP Inhibitors as Novel Immune Adjuvants for Scaffold Based Cancer Vaccines

  2015cites this paper
• Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

  2015cites this paper
• Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.

  2015cites this paper
• Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.

  2015cites this paper
• Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer

  2015cites this paper
• The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

  2014cites this paper
• Modes of action of TLR7 agonists in cancer therapy.

  2014cites this paper
• Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

  2014cites this paper
• A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response.

  2014cites this paper
• Relevance of Nck–CD3ε Interaction for T Cell Activation In Vivo

  2014cites this paper
• This information is current as Activation Immunity through Localized TLR 7 / 8 Effective Innate and Adaptive Antimelanoma

  2014cites this paper
• Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy

  2014cites this paper
• Direct T Cell Activation via CD40 Ligand Generates High Avidity CD8+ T Cells Capable of Breaking Immunological Tolerance for the Control of Tumors

  2014influential citation
• Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation

  2014cites this paper
• Dual Role of TLR3 in Inflammation and Cancer Cell Apoptosis

  2013cites this paper
• Dual Role of TLR 3 in Inflammation and Cancer Cell Apoptosis

  2013cites this paper
• A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell Responses In Vivo

  2013influential citation
• The regulation of toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells

  2013cites this paper
• Adjuvant Strategies for Vaccines: The Use of Adjuvants within the Cancer Vaccine Setting

  2013cites this paper
• Characterisation of high and low avidity peptide specific CD8+ T cells using immunologic, transcriptomic and proteomic tools

  2013cites this paper
• The role of Ikaros in CD8+ T cell biology

  2013cites this paper
• Adhesion Molecule Regulation of Regulatory T Cell Migration

  2013cites this paper
• Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep.

  2012cites this paper
• Design and validation of novel cross-reactive influenza B vaccines

  2012cites this paper
• Immunotherapy for melanoma

  2012cites this paper
• Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep.

  2012influential citation
• T-cell-independent Antitumor Effects of CD40 Ligation

  2012cites this paper
• Targeting pattern recognition receptors in cancer immunotherapy

  2012cites this paper
• Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo.

  2012cites this paper
• Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

  2012cites this paper
• Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

  2012cites this paper
• Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells?

  2012cites this paper
• The Immune Response to Tumors as a Tool toward Immunotherapy

  2011cites this paper